entry inhibitors targeting SARS-CoV-2 spike protein RBD (University of Nebraska Medical Center/University of Missouri)

N/A

Report date: 2025/06/11 11:17:22
NME

Base Information

Drug Nameentry inhibitors targeting SARS-CoV-2 spike protein RBD (University of Nebraska Medical Center/University of Missouri)
Drug Alias NameGK-03168MU-UNMC-2RJC-03545MU-UNMC-1
ClassificationSmall molecules
Mechanisms of ActionCoronavirus spike glycoprotein modulatorsAngiotensin-converting enzyme 2 modulators
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Nebraska Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Nebraska Medical CenterUniversity Of Missouri
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A